Galunisertib

Combination therapies targeting pancreatic cancer's extracellular stroma and membrane receptors show promise. Hyaluronidase and anti-PD-L1/PD-1 antibodies enhance tumor growth inhibition. IL-6 blockade with anti-PD-L1 improves survival. VDR ligands and TGF-β inhibitors combined with checkpoint inhibitors increase T cell infiltration. CD40 agonists and CXCR4 inhibitors with anti-PD-1 show potential in enhancing anti-tumor immunity. FAK and BTK inhibitors, alongside PARP inhibitors, are being explored for their roles in improving treatment efficacy.